Bayer agrees to help make CureVac’s COVID-19 vaccine

BERLIN (Reuters) – German pharmaceutical giant Bayer said on Monday it will help CureVac produce its experimental COVID-19 vaccine, the latest drugmaker to offer up manufacturing capacity as supplies fall behind demand.

 

Bayer said it expects to produce 161 million doses of CureVac’s experimental vaccine, which is currently in late-stage testing, in 2022, its head of pharma Stefan Oelrich told a news conference. (Reporting by Caroline Copley; editing by Thomas Seythal)

 

facebookShare on Facebook
TwitterPost on X
FollowFollow us
PinterestSave

Related Posts

‘Munhumutapa legacy informs the present’ . . . Courage, innovation, hard work and self-determination our key attributes
‘Munhumutapa legacy informs the present’ . . . Courage, innovation, hard work and self-determination our key attributes

Nyore Madzianike-Senior Reporter The rich history of the great Munhumutapa Empire symbolises Zimbabwe’s identity and capacity to govern itself, with the Second Republic mirroring the administration and organisational structures of…

Continue reading
Do your best always, President rallies youth
Do your best always, President rallies youth

Joseph Madzimure-Zimpapers Reporter President Mnangagwa has called upon the youth never to  settle for average, but to work hard and make clean money, following in the footsteps of the innovative…

Continue reading

Leave a Reply

Your email address will not be published. Required fields are marked *